Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics to Sequence Genome of Undisclosed Pathogen for Wyeth-Lederle

NEW YORK, Feb 1 – Genome Therapeutics has agreed to sequence the genome of an undisclosed pathogenic organism for Wyeth-Lederle Vaccines, the companies said Thursday.

The name of the pathogen remains confidential under the agreement, and Wyeth-Lederle Research spokesman Doug Petkus would say only that the genome “will be useful for our discovery efforts.”

Genome Therapeutics, based in Waltham, Mass., maintains a database of more than 30 pathogens, including Staphylococcus, Pseudomonas, and Streptococcus species, that is available to the public on a pay-per-use basis through Compugen’s Last October, the company completed the sequence of Proteus mirabilis and Klebsiella pneumoniae , which are both implicated in urinary tract infections.

Petkus said the present agreement focuses only on obtaining the sequence of the genome, but that Wyeth might ask for additional annotations in the future. The contract does not set a time limit on the project, added Petkus.

Genome Therapeutics operates the GTC Sequencing Center, which offers genomics sequencing, cDNA and PCR sequencing, SNP detection and other specialized sequencing services. Some of the company's current customers include AstraZeneca, Aventis, and the Rat Genome Sequencing Network.

“We are pleased Wyeth-Lederle selected the GTC Sequencing Center for its genomic services needs and look forward to augmenting their research through this project,” said Steven Rauscher, Genome Therapeutics’ CEO in a statement.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.